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Abstract
Background: Pulmonary deterioration after B.cepacia complex (BCC) colonization has a heterogeneous pattern.
The aim was to investigate the clinical outcome of BCC colonization in CF patients chronically colonized with
P. aeruginosa.
Methods: CF patients chronically colonized with P. aeruginosa were divided into three groups: intermittent (I),
chronic (II) and no colonization (III) with BCC. Body mass index (BMI) percentile and spirometric parameters were
analyzed at three different times in each group.
Results: Fifty-six patients chronically colonized with P. aeruginosa were included. Of these, 27 also had evidence
of BCC colonization (13 intermittent and 14 chronic). BMI percentile was significantly lower among patients
chronically colonized by both P. aeruginosa and BCC. Mean values of FEV1 and FVC % were also significantly
lower in these patients, both at the time of chronic BCC colonization and 24 months forward.
Conclusions: Chronic BCC colonization is associated with significant loss of lung function. Lower BMI might be
a risk factor for chronic BCC colonization, preceding these events.
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Key messages
 Chronic BCC colonization is associated with
significant loss of lung function
 Lower BMI might be a risk factor for chronic BCC
colonization
Background
Respiratory disease is the major cause of morbidity and
mortality in cystic fibrosis (CF) patients. The majority of
CF patients develop chronic infection by Pseudomonas
aeruginosa, which is associated with impaired lung func-
tion and decreased survival in CF [1].
Burkholderia cepacia complex (BCC) is now recognized
as a group of opportunistic pathogens in CF patients,
usually associated with poor prognosis and patient-to-
patient transmissibility. The exact pathophysiology of BCC
colonization/infection remains unclear, and pulmonary de-
terioration has a heterogeneous pattern, leading to a ful-
minant development in almost 30 % of patients [2, 3].
Loss of lung function is still one of the main factor
that contribute to mortality in CF [4]. Therefore, spiro-
metric measurements – in particular, forced expiratory
volume in 1 s (FEV1) % predicted and forced vital cap-
acity (FVC) % predicted – are important surrogate mea-
sures of disease progression [4]. Nutritional status has a
strong positive association with pulmonary function and
survival in CF. Attainment of normal body mass index
(BMI) is one of the major goals for CF treatment.
The aim of this study was to investigate the clinical
outcome of BCC colonization in CF patients who were
previously chronically colonized with P. aeruginosa.
Methods
This is a retrospective study performed in two CF cen-
tres in Rio de Janeiro, Brazil: Instituto Fernandes Fig-
ueira (Fundação Oswaldo Cruz, Ministério da Saúde),
for children/adolescents, and Hospital Universitário
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Pedro Ernesto – HUPE (Universidade do Estado do Rio
de Janeiro – UERJ), for adults. Approval was obtained
from the ethics committee on both institutions.
In both institutions, cultures of respiratory secretions
were conducted in the Bacteriological Laboratory of
HUPE/UERJ, according to standardized protocols estab-
lished for CF patients, and were performed at least on a
3- monthly basis throughout the study [5]. The clinical
samples were plated onto Sheep blood agar, MacConkey
agar, Mannitol salt agar (Difco Labs, Detroit, MI, USA)
and Burkholderia cepacia medium supplemented (Oxoid,
Basingstoke, England). The microorganisms were charac-
terized at the genus and species level by routine conven-
tional physiological methods [6]. In order to identify the
distinct genomovars, a 1043 bp PCR product correspond-
ing to the recA gene was amplified by PCR. DNA se-
quence was performed in both directions with the PCR
primers and the aid of two additional primers, BCR3 and
BCR, as previously described [7, 8].
Patients’ inclusion criteria were: CF diagnosis accord-
ing to Cystic Fibrosis Foundation consensus [9, 10];
regular clinical and laboratorial follow-up during the
study period; chronic colonization with P. aeruginosa
diagnosis (i.e., happened before the study period and
was diagnosed when P. aeruginosa was isolated in more
than 50 % of cultures of sputum or throat swabs taken
in the previous 12-month period) [11]. Subjects who
presented no respiratory colonization or solely S. aureus
colonization were excluded from the study, as well as
those who were being submitted to any kind of P. aeru-
ginosa eradication protocol.
These patients (all chronically colonized with P. aeru-
ginosa) were divided into the following groups:
Group I – patients with intermittent colonization with
BCC (1 or 2 isolates per year)
Group II – patients with chronic colonization with
BCC (3 or more isolates per year)
Group III – patients never colonized with BCC
For each patient, medical record data was evaluated,
including gender, age, genotype and diagnostic criteria,
state of pancreatic insufficiency (fecal fat or fecal elastase
or need for exogenous replacement enzymes), CF-
related diabetes (CFRD) and liver disease. The clinical
outcome of each patient was also evaluated considering
the following parameters: spirometric parameters such
as forced expiratory volume in 1 s (FEV1) % predicted
and forced vital capacity (FVC) % predicted, and body
mass index (BMI) percentile for patients 2–19 y/o. These
data were recorded for all groups during three different
times (Fig. 1): Time 1: when patient was diagnosed as hav-
ing P. aeruginosa chronic colonization; Time 2: when
group II was diagnosed as having chronic colonization with
BCC; since median time between the chronic colonization
with P. aeruginosa and the chronic colonization with BCC
was 3 years, this period of time was used to establish Time
2, for groups I and III; Time 3: all patients were also evalu-
ated 5 years after the P. aeruginosa chronic colonization.
Descriptive statistical analyses were performed through
construction of tables and charts. Non-parametric
Mann–Whitney and Kruskal-Wallis tests were used to
compare numerical and categorical variables with 2 or 3
categories respectively. The Wilcoxon test was used to
analyze statistical significance of temporal variations
within each group. The level of significance was set at
probability (p) less than 5 % (p < 0.05).
Results
From 2004 to 2013, 56 patients with chronic P. aerugi-
nosa colonization were identified. Of these, 27 also had
evidence of BCC colonization: 13 had intermittent
colonization and 14 had chronic colonization. Clinical
data is described in Table 1. Age of patients at the inclu-
sion time ranged from 0 to 36 years old, most of them
female (n = 38, 67.9 %); the majority were children or ado-
lescents (n = 52; 92.9 %). Diabetes mellitus (CFRD) and
liver disease related to CF were uncommon (3.6 and 1.8 %,
respectively), whereas pancreatic insufficiency was present
TIME 1
P. aeruginosa chronic 
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in most of the population (94.6 %). Regarding chronic
colonization, no patients were chronically colonized for H.
Influenzae, Achromobacter spp and Stenotrophomonas spp.
Chronic colonization with S. aureus was found in 84.6 % in
group I, 28.5 % in group II and 92.6 % in group III. Fur-
thermore, chronic colonization with methicillin-resistant S.
aureus was found in 7.7 % in group I, 0 % in group II and
7.4 % in group III.
The average number of hospital admissions per year
was 0.7, with no statistical difference among the groups.
At each hospital admission, patients received intravenous
antibiotic treatment. All patients with new growths of
BCC were treated with a regimen of 3 intravenous antibi-
otics (meropenem+ ceftazidime + amykacin) for 2 weeks,
followed by 3 consecutive months of nebulised tobra-
mycin. If BCC is isolated after initial colonization, patients
received another course of step I. For further CBC isola-
tion, therapeutic management was discussed by the multi-
disciplinary team. Death occurred in 7 patients (2 in
group I and 5 in group II). No patient died in group III
during the 5 years of observation.
Spiromeric data (FEV1 % and FVC % predicted) and
BMI percentile were evaluated for all groups in the three
different times previously described. Spirometric data
were obtained from 49 of the 56 patients involved in the
study: 10 of 13 patients in group I, 13 of the 14 patients
in group II and 26 of the 29 patients in group III. The
limiting factors for spirometry performance were: age
less than six years old (6 patients), and neurological
problems (1 patient).
There was no statistically significant difference between
the groups for FEV1 % predicted (p-value: 0.267) or FVC
(p-value: 0.911) at the time of P. aeruginosa chronic infec-
tion. However, at this time, patients of group II (who
would course with chronic colonization with BCC 3 years
later) already presented BMI percentiles significantly
lower (mean: 17.8) than the other groups (mean: 41.4 and
53.9), and p-value was 0.002 (Table 2).
Three years later, when patients from group II were di-
agnosed with chronic infection by BCC, mean values of
FEV1 % predicted, FVC % predicted and BMI percentile
were lower in group II, without statistical significance
(p-value >0.05) (Table 2).
Five years later, mean values of FEV1 % predicted and
FVC % predicted were significantly lower in patients
chronically colonized with BCC (52.3 %; 67.8 %) when
compared with those with intermittent colonization by
BCC and those never colonized with BCC (p-values
0.004 and 0.032, respectively). Surprisingly, mean values
of FEV1 % predicted and FVC % predicted for patients
with intermittent BCC colonization were higher than
those who were never colonized by BCC. At the end of
the study (5 years after the P. aeruginosa chronic
colonization), the mean value of the BMI percentile was
significantly lower in patients with chronic BCC (21.1)
than it was in groups I and III (45.4 and 45.6, respect-
ively) with p-value 0.035 (Table 2).
Mean annual rates of decline for spirometric data
(FEV1 and FVC % predicted) were statistically different
between the groups. While group I (intermittent
colonization with BCC) and III (never colonized with
BCC) showed mean FEV1 % predicted annual rates of
decline of 0 ± 2.9 % and −2.6 ± 2.9 % respectively, pa-
tients chronically colonized with BCC presented with a
mean FEV1 % predicted annual rate of decline of −6 ±
6.0 %. When assessing FVC % predicted, mean annual
rates of decline in intermittent or never colonized pa-
tients with BCC were 0.6 ± 2.5 % and −2.2 ± 2.9 %, re-
spectively, while patients chronically colonized with
BCC presented with −6 ± 7.9 % (Table 3).
In a subanalysis restricted to patients chronically colo-
nized with B. cepacia complex bacteria, it was found that
most of them had B. cenocepacia (n = 8) and B. vietna-
miensis (n = 5). Analyzing spirometric data of FEV1 and
FVC % predicted, there were no statistical differences
between species in this group of patients. However, we
noted a greater number of deaths in B. cenocepacia
chronically colonized patients.
Discussion
Previous studies have found that CF patients chronically
colonized with BCC have a greater deterioration of lung
function, require more frequent antibiotic therapy and
also display increased mortality compared to patients
colonized with P. aeruginosa [12, 13].
Table 1 Patient data
Group I Group II Group III p-value
Gender (n) 0.056*
Male 4 8 6
Female 9 6 23
Age (mean age at time 1, in years) 9.2 11.1 9.4 0.744**
Mean annual hospital admissions per year 1.2 0.7 0.5 0.601**
*Obtained by Χ2 test
**Obtained by Kruskall-Wallis test; Level of significance: p-value < 0.05
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Although the clinical outcome after chronic P. aerugi-
nosa colonization has been extensively analyzed and as-
sociated with deterioration of lung function, few studies
have been done with chronic BCC colonization. McClos-
key et al [14] assessed the impact of BCC infection in
adult CF patients by measuring changes in pulmonary
function and BMI in patients previously infected or
never infected with P. aeruginosa. They concluded that
infection with BCC results in a more rapid but variable
lung function decline, which may be related to the strain
involved. However, in all groups involved, there was no
mention about chronicity of infection.
Correia et al [2] carried out a retrospective study of 31
patients with BCC infection who were categorized into
two groups (I: intermittent isolations and II: chronic isola-
tions). As expected, in the chronic isolation group, pa-
tients had higher mortality and number of hospitalizations
and lower FEV1 values, in line with patients’ major deteri-
oration. Some patients from the chronic isolation group
had already exhibited deteriorated lung function before
becoming infected with BCC, as a result of colonization
with other pathogenic agents and disease progression.
There was no comparative data between both groups re-
garding co-infection, lung function or BMI.
Table 2 Espirometric and BMI percentile data














FEV1 % I 78.9 27.0 0.267 82.9 27.9 0.176 86.6 22.3 0.004
II 70.6 17.2 66.4 22.4 52.3 20.1
III 81.5 22.2 72.6 22.3 67.0 18.8
Total 78.2 21.8 73.1 23.7 66.7 22.5
FVC % I 85.5 24.2 88.9 23.4 93.6 18.7 0.032
II 86.5 18.3 0.911 80.8 18.7 0.426 67.8 21.2
III 89.3 19.2 82.0 19.4 78.0 16.7
Total 87.9 19.4 83.1 19.9 78.1 19.9
BMI percentile I 41.4 25.4 43.5 26.9 45.4 20.8 0.035
II 17.8 19.5 0.002 22.3 20.5 0.082 21.1 15.0
III 53.9 30.3 45.7 29.2 45.6 28.4
Total 42.2 30.6 39.8 28.1 39.8 26.1
Group I: patients with intemittent colonization with B. cepacia complex bacteria (1 or 2 isolates per year)
Group II: patients with chronic colonization with B. cepacia complex bacteria (≥3 isolates per year)
Group III: patients never colonized with B. cepacia complex bacteria
FEV1 %: forced expiratory volume in 1 s % predicted
FVC %: forced vital capacity % predicted
BMI percentile: body mass index percentile
p-value obtained by Wilcoxon test (level of significance: p-value < 0.05)
Table 3 Spirometric data (Annual rate of decline: FEV1 % and FVC % predicted)
Group Number Mean Standard deviation P-value Kruskall-Wallis
FEV1 % I 10 0.0 2.9 0.002
II 13 -6.0 6.6
III 26 -2.6 2.9
Total 49 -3.0 4.6
FVC % I 10 0.6 2.5 0.010
II 13 -6.0 79
III 26 -2.2 2.9
Total 49 -2.6 5.2
Number: number of patients who performed spirometry
Group I: patients with intermittent colonization with B. cepacia complex bacteria (1 or 2 isolates per year)
Group II: patients with chronic colonization with B. cepacia complex bacteria (≥3 isolates per year)
Group III: patients never colonized with B. cepacia complex bacteria
FEV1 %: forced expiratory volume in 1 s
FVC %: forced vital capacity
Level of significance p-value <0.05
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In our study, a higher number of deaths occurred in
the BCC chronically colonized group. All patients in our
study were previously diagnosed as having P. aeruginosa
chronic infection. This aspect is relevant because the de-
terioration of any criteria in all groups wouldn’t be associ-
ated with Pseudomonas aeruginosa, a bacteria currently
known to have impact on CF lung disease, and, therefore,
eliminating this possible bias [4].
Patients who developed chronic colonization with
BCC demonstrated significant lower FEV1 and FVC at
this time, showing that B. cepacia complex chronic
colonization might be a risk factor for lung volume de-
cline. Higher mean values of FEV1 and FVC were found
for patients with intermittent B. cepacia complex
colonization. This might be related to a better patient
and family adherence to treatment since first isolation of
B. cepacia complex. The knowledge of the decrease in
long-term survival and fear of progressive invasive
bacteremic disease associated with BCC colonization
might be responsible for this change in attitude regard-
ing CF treatment.
The rate of decline in FEV1 % predicted has been stud-
ied in CF patients to better understand the progression
of lung disease, in order to identify high-risk groups in
whom aggressive therapy might be indicated and to as-
sess therapeutic interventions. Risk factors associated
with FEV1 decline include but are not limited to young
age, high lung function, female gender, modifier genes,
pancreatic insufficiency, poor nutritional status, viral re-
spiratory infections, colonization with P. aeruginosa and
BCC, and diabetes mellitus. The Epidemiologic Study of
Cystic Fibrosis found that overall rates of FEV1 % pre-
dicted decline were −1.12, −2.39 and −2.34 % per year in
6–8-year-olds, 9–12-year-olds and 13–17-year-olds, re-
spectively [15].
Frangolias et al [16], comparing two groups of adult
CF patients (infected and not infected with BCC), found
no significant differences in rates of FEV1 and FVC %
predicted decline between cases and controls. In our
study, mean rates of FEV1 % predicted decline were sta-
tistically different between the groups, and the group
chronically colonized with BCC presented with a mean
FEV1 % predicted decline of −6 % per year, which was
much higher than expected in all ages. This shows the
negative impact of chronic BCC infection in CF lung
disease.
The association of better nutritional status with im-
provement of lung function is well documented, and poor
nutrition is a risk factor for accelerated decline in lung
function. However, it is not known whether BMI decline
predates FEV1 decline. A retrospective study by Mc Phail
et al [17] compared lung function and nutritional outcome
in two CF birth cohorts. They found improvements in
lung function and nutritional status in patients from ages
6–12, and a decreased rate of lung function decline associ-
ated with a higher baseline BMI (% predicted) and a
slower rate of BMI decline. In our study, the BCC chron-
ically colonized group had a lower baseline BMI, which
might be a risk factor for chronic BCC colonization and
disease progression.
Many studies have shown that in pulmonary colonization
with B. cepacia complex, the outcome varies considerably,
from a rapid fatal decline in lung function and bacteremia
to an acceleration of pulmonary function decline or to
chronic asymptomatic infection, suggesting that pathogen-
icity within B. cepacia complex varies [12]. In our study, B.
cenocepacia was more frequent in the chronically colo-
nized group (8/14). In this group, the number of deaths
was higher and associated with B. cenocepacia colonization
in 80 % of cases (4/5). B. vietnamiensis was isolated in
one patient of group II who died (1/5). Mean time of
death after chronic colonization with BCC was 5.2 years.
Considering only the four patients with B. cenocepacia
colonization, this time was reduced to 4.7 years.
Understanding functional consequences of CFTR mu-
tations is important not only for population screening
but also CF for management and treatment. McManus
et al [18] performed genotype analysis on 59 adult CF
patients and evaluated its correlation to P. aeruginosa
and BCC chronic infection. They concluded that pa-
tients homozygous or heterozygous for the deltaF508
deletion are more likely to suffer airway colonization
with BCC or P. aeruginosa. In our study, CF genotype
was not available for all patients. Further evaluation of
CF genotype will be useful to understand correlation of
CF genotype and BCC colonization.
The retrospective nature of the study and the strict in-
clusion criteria limited the sample size. However, there
are few studies contemplating BCC infection involving
children and adults with CF.
Conclusion
In conclusion, this study suggests that in patients previ-
ously identified as chronically colonized with P. aerugi-
nosa, chronic BCC colonization is associated with lower
spirometric data. However, lower BMI might preceed
spirometric effects of BCC, possibly being a risk factor
for chronic colonization.
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